Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
-
Published:2024-09
Issue:9
Volume:9
Page:103684
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Triner D.,
Graf R.P.ORCID,
Madison R.W.ORCID,
Gjoerup O.ORCID,
Tukachinsky H.,
Ross J.S.ORCID,
Quintanilha J.C.F.,
Li G.ORCID,
Cheng H.H.,
Pritchard C.C.ORCID,
Zurita A.J.ORCID,
Qin Q.,
Zhang T.,
Agarwal N.ORCID,
Reichert Z.R.ORCID,
Mateo J.,
Cieslik M.,
Morgan T.M.ORCID